期刊
ANNUAL REVIEW OF MEDICINE, VOL 70
卷 70, 期 -, 页码 45-59出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev-med-041717-085955
关键词
hypertension; pulmonary; right heart failure; clinical trials; humans; pulmonary arterial treatment
资金
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K24HL103844] Funding Source: NIH RePORTER
- NHLBI NIH HHS [R01 HL134776, K24 HL103844, R01 HL139664] Funding Source: Medline
Pulmonary arterial hypertension (PAH) is a pulmonary vasculopathy that causes right ventricular dysfunction and exercise limitation and progresses to death. New findings from translational studies have suggested alternative pathways for treatment. These avenues include sex hormones, genetic abnormalities and DNA damage, elastase inhibition, metabolic dysfunction, cellular therapies, and anti-inflammatory approaches. Both novel and re-purposed compounds with rationale from preclinical experimental models and human cells are now in clinical trials in patients with PAH. Findings from these studies will elucidate the pathobiology of PAH and may result in clinically important improvements in outcome.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据